Hemophilia A

Inclusion Criteria

- Male, 2-＜18 years
Hemophilia A, based on documented prior testing and/or screening laboratory
Patients who had received regular prophylaxis/bleeding prevention treatment, totally/partially with rFⅧ. Regular prophylaxis/bleeding prevention treatment is defined as that proportion of weeks (≥2 infusion/week) of total treatment weeks≥80%[10] , and total duration ≥12 weeks. During the regular prophylaxis period, if there were consecutive 4 weeks that ＜2 infusion/week, the beginning day of the 4 weeks is defined as the end of regular prophylaxis.
Available patient medical data record
Written informed consent by parent/legal representative. Consent should be sought from subjects if appropriate

Exclusion Criteria

- Patients with measurable inhibitor activity at baseline and history of FVIII inhibitor antibody formation (≥0.6BU by Bethesda assay at two different time points, documentation must be available)
Any individuals with another bleeding disease that is different from hemophilia A (e.g, von Willebrand disease, hemophilia B)